Other name:ATL-962,Cetilistat (ATL-962),New alistat,"Oblean"
CAS: 282526-98-1
Molecular Formula:C25H39NO3
MolecularWeight::401.58
Source: Synthetic
Appearance: White to off white powder
Assay :≥99.0%
Heavy metals: <10PPM
Cetilistat also known as Cetilistat (ATL-962) and Cetislim, is a new gastrointestinal lipase inhibitor developed by the British company Alizyme, and later "NorginaBV" has won the global agency of "cetiristone Chemicalbook". Cetirista is conducting a phase 3 clinical trial in the United States. In Japan, in cooperation with Takeda Pharmaceuticals, neolilitar was approved as a drug for the treatment of obesity in September 2013. The name of the product is "Oblean".
Itis a new pancreatic lipase inhibitor for the treatment of obesity in diabetic and non-diabetic patients.
Cetilistat is a drug designed to treat obesity. It acts in the same way as the older drug orlistat(Xenical) by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being ...
Company Profile Jiangsu kaihuida New Material Technology Co., Ltd. is a scientific and technological company engaged in the development, production and operation of chemical products. It is a comprehensive enterprise integrating scientific and Technological Development and mass ...